SCHEMBL6768667

SCHEMBL6768667

Cn1c(=O)c(-c2ccc(F)cc2)c(-c2ccnc(NCc3ccccc3N)n2)n1C1CCNCC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 18/20 0.47
MAPK13 O15264 12/20 0.47
MAPK12 P53778 12/20 0.47
MAPK11 Q15759 12/20 0.47
BRD4 O60885 2/20 0.41
BRD2 P25440 2/20 0.41
BRD3 Q15059 2/20 0.41
BRDT Q58F21 2/20 0.41
RIPK2 O43353 1/20 0.41
DYRK3 O43781 1/20 0.41
PRKD3 O94806 1/20 0.41
MAP4K4 O95819 1/20 0.41
PRKCG P05129 1/20 0.41
LCK P06239 1/20 0.41
LYN P07948 1/20 0.41
RET P07949 1/20 0.41
PIM1 P11309 1/20 0.41
PRKACA P17612 1/20 0.41
MAPK1 P28482 1/20 0.41
FLT4 P35916 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6768682 0.92 MAPK14 (0.49) MAPK14MAPK13MAPK12MAPK11BRD4
SCHEMBL6766744 0.89 MAPK14 (0.61) MAPK14MAPK13MAPK12MAPK11BRD4
SCHEMBL6763952 0.88 MAPK14 (0.54) MAPK14MAPK13MAPK12MAPK11BRD4
SCHEMBL6769365 0.87 MAPK14 (0.51) MAPK14MAPK13MAPK12MAPK11BRD4
SCHEMBL6767240 0.86 MAPK14 (0.50) MAPK14MAPK13MAPK12MAPK11BRD4
SCHEMBL6768619 0.85 MAPK14 (0.52) MAPK14MAPK13MAPK12MAPK11BRD4
SCHEMBL6768661 0.81 MAPK14 (0.42) MAPK14MAPK13MAPK12MAPK11BRD4
SCHEMBL6621254 0.81 MAPK14 (0.63) MAPK14MAPK13MAPK12MAPK11PRKD3
SCHEMBL6621251 0.81 MAPK14 (0.63) MAPK14MAPK13MAPK12MAPK11PRKD3
SCHEMBL6618659 0.80 MAPK14 (0.58) MAPK14MAPK13MAPK12MAPK11BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6677337-B2 RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, INFLAMMATORY BOWEL DISEASE, CACHEXIA, SEPTIC SHOCK, CARDIOVASCULAR AND RESPIRATORY SYSTEM DISORDERS THE PROCTER & GAMBLE COMPANY 2004-01-13 US claimed
US-20030225082-A1 1,2-dihydropyrazol-3-ones which controls inflammatory cytokines PROCTER & GAMBLE COMPANY, THE 2003-12-04 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225082-A1 1,2-dihydropyrazol-3-ones which controls inflammatory cytokines IL1B, IL1A, IL1R1 MAPK14 1086/4885MAPK13 1053/4885MAPK12 997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.